Company intelligence / Profile preview
Nicox S.A.
Sophia Antipolis, Francenicox.com ↗
- Ownership
- Public · ALXP
- Development stage
- Phase 3
01
Overview
Lead program NCX 470 is in Phase 3 clinical development for glaucoma. In clinical trials, NCX 470 demonstrated superior IOP lowering compared to latanoprost by up to 1.0 mmHg, with ocular hyperemia as the most common adverse event (11.9% vs 3.3% for latanoprost)[4]. The company has two FDA-approved products already commercialized in the US: VYZULTA for glaucoma and ZERVIATE for allergic conjunctivitis[1][2].
- Therapeutic areas
- OphthalmologyImmunology
- Modalities
- Small moleculesnitric oxide-donating compounds
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Bausch & LombHarrow Inc. (formerly Eyevance Pharmaceuticals)Ocumension Therapeutics
Beyond the preview
Go deeper on Nicox S.A..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nicox S.A..